Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?
Over 80% of crs with nasal polyps’ patients have type 2 inflammation dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.
.png/jcr:content/image%20(86).png)
.png0/jcr:content/1%20(2).png)
.png/jcr:content/2%20(3).png)
.png0/jcr:content/3%20(2).png)
MAT-KW-2400275/V1/MAY2024